Cat. No. 3571
Chemical Name: 2-Bromo-N-[4-chloro-3-[[(3R)-1-meth
Biological ActivitySelective urotensin-II (UT) receptor antagonist (Ki values are 61, 17, 30, 65 and 56 nM at human, monkey, cat, rat and mouse receptors respectively). Inhibits U-II-induced intracellular Ca2+ mobilization (IC50 = 180 nM) and antagonizes the contractile action of U-II in isolated mammalian arteries and aortae (EC50 = 50 - 189 nM).
Licensing InformationSold with the permission of GlaxoSmithKline
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Behm et al (2008) Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br.J.Pharmacol. 155 374. PMID: 18587423.
Douglas et al (2005) Nonpeptide urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br.J.Pharmacol. 145 620. PMID: 15852036.
If you know of a relevant reference for SB 657510 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SB 657510 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SB 657510, supplier, SB657510, UT-II, urotensin-II, receptors, antagonists, GlaxoSmithKline, Tocris Bioscience, Urotensin-II Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailableML 233
Non-peptide apelin receptor agonist
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.